tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'TD2'

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...

Read More →
0

PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study

PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study

Written by Ι Stock Market Media — June 3, 2015

NEW YORK, NY — PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.

It was a study ...

Read More →
0

PharmaCyte Biotech Equity Research by Stonegate Capital Partners

PharmaCyte Biotech Equity Research by Stonegate Capital Partners

On May 28, 2015, Stonegate Capital Partners released an extensive Equity Research Report on PharmaCyte Biotech, Inc.  The firm’s reports are issued to targeted funds, and institutional investors also have access to Stonegate’s research from a variety of services including Bloomberg, Thomson Reuters, Zach’s, Capital IQ, The Markets, Morningstar and FactSet among others. Stonegate has the ability to actively track the institutional investors who access their research.

Click to View Stonegate Capital Partners Equity Research on PharmaCyte ...

Read More →
0

PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials

PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials

Written by Ι Stock Market Media Group  — April 23, 2015

PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The international biotech firm is already set to head into Phase 2b clinical trials in advanced inoperable pancreatic cancer later this year in Australia. PharmaCyte even made headlines in the diabetes industry two weeks ago after a study was published that stated its Melligen cell line could produce ...

Read More →
0

Nuvilex Announces Name Change to PharmaCyte Biotech

Nuvilex Announces Name Change to PharmaCyte Biotech

Company’s Shares Will Trade Under New Ticker Symbol PHCB

SILVER SPRING, MD., Jan. 7, 2015 — Nuvilex, Inc. (NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change ...

Read More →
0

FDA Grants Orphan Drug Designation to Nuvilex, Inc. for Pancreatic Cancer Treatment

SILVER SPRING, Md., Dec. 22, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box(R), with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are ...

Read More →
0
Page 1 of 3 123
ContactUs.com